- Home
- RGS vs BOLD Comparison
RGS vs BOLD Comparison
Compare RGS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGS | BOLD |
|---|---|---|
| Founded | 1922 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.3M | 26.9M |
| IPO Year | 1991 | 2024 |
Fundamental Metrics
Financial Performance| Metric | RGS | BOLD |
|---|---|---|
| Price | $25.66 | $1.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.7K | ★ 127.7K |
| Earning Date | 02-11-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.05 | N/A |
| EPS | ★ 45.08 | N/A |
| Revenue | ★ $223,032,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.60 | ★ N/A |
| Revenue Growth | ★ 13.98 | N/A |
| 52 Week Low | $15.00 | $1.00 |
| 52 Week High | $31.50 | $2.77 |
Technical Indicators
Market Signals| Indicator | RGS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 35.74 | 56.47 |
| Support Level | $26.27 | $1.14 |
| Resistance Level | $27.75 | $1.24 |
| Average True Range (ATR) | 0.86 | 0.08 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 5.92 | 46.00 |
Price Performance
Historical ComparisonAbout RGS Regis Corporation
Regis Corporation owns, franchises, and operates beauty salons in North America and the U.K., serving mainly price-conscious customers. Its salons, located mostly in strip malls, shopping centers, and Walmart stores, offer services like haircutting, styling, shampooing, conditioning, and hair coloring, along with hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, and Cost Cutters. Regis generates the majority of its revenue from these mass-market locations and reports operations in two segments: franchise and company-owned, with services making up about 94% of company-owned salon sales.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.